drugset / Trial / NCT06120166

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

NCT06120166 ↗

Phase 0 Recruiting 18 enrolled He Huang Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment

Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma

Timeline

Start
2023-11-16
Primary completion
2025-12-01
Completion
2026-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Metabolically Armed CD19 CAR-T cells Cell therapy — Intravenous